CCAT 1- A Pivotal Oncogenic Long Non-Coding RNA in Colorectal Cancer.

IF 2.7 4区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

British Journal of Biomedical Science Pub Date : 2023-01-01 DOI:10.3389/bjbs.2023.11103

Xiew Leng Liau, Shamala Salvamani, Baskaran Gunasekaran, Dinesh Kumar Chellappan, Anthony Rhodes, Vaidehi Ulaganathan, Yee Lian Tiong

{"title":"CCAT 1- A Pivotal Oncogenic Long Non-Coding RNA in Colorectal Cancer.","authors":"Xiew Leng Liau, Shamala Salvamani, Baskaran Gunasekaran, Dinesh Kumar Chellappan, Anthony Rhodes, Vaidehi Ulaganathan, Yee Lian Tiong","doi":"10.3389/bjbs.2023.11103","DOIUrl":null,"url":null,"abstract":"Colorectal cancer (CRC) is ranked as the third most common cancer and second deadliest cancer in both men and women in the world. Currently, the cure rate and 5-year survival rate of CRC patients remain relatively low. Therefore, discovering a novel molecular biomarker that can be used to improve CRC screening, diagnosis, prognosis, and treatment would be beneficial. Long non-coding RNA colon cancer-associated transcript 1 (CCAT 1) has been found overexpressed in CRC and is associated with CRC tumorigenesis and treatment outcome. CCAT 1 has a high degree of specificity and sensitivity, it is readily detected in CRC tissues and is significantly overexpressed in both premalignant and malignant CRC tissues. Besides, CCAT 1 is associated with clinical manifestation and advanced features of CRC, such as lymph node metastasis, high tumor node metastasis stage, differentiation, invasion, and distant metastasis. In addition, they can upregulate oncogenic c-MYC and negatively modulate microRNAs via different mechanisms of action. Furthermore, dysregulated CCAT 1 also enhances the chemoresistance in CRC cells while downregulation of them reverses the malignant phenotypes of cancer cells. In brief, CCAT 1 serves as a potential screening, diagnostic and prognostic biomarker in CRC, it also serves as a potential therapeutic marker to treat CRC patients.","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070472/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Biomedical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/bjbs.2023.11103","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Colorectal cancer (CRC) is ranked as the third most common cancer and second deadliest cancer in both men and women in the world. Currently, the cure rate and 5-year survival rate of CRC patients remain relatively low. Therefore, discovering a novel molecular biomarker that can be used to improve CRC screening, diagnosis, prognosis, and treatment would be beneficial. Long non-coding RNA colon cancer-associated transcript 1 (CCAT 1) has been found overexpressed in CRC and is associated with CRC tumorigenesis and treatment outcome. CCAT 1 has a high degree of specificity and sensitivity, it is readily detected in CRC tissues and is significantly overexpressed in both premalignant and malignant CRC tissues. Besides, CCAT 1 is associated with clinical manifestation and advanced features of CRC, such as lymph node metastasis, high tumor node metastasis stage, differentiation, invasion, and distant metastasis. In addition, they can upregulate oncogenic c-MYC and negatively modulate microRNAs via different mechanisms of action. Furthermore, dysregulated CCAT 1 also enhances the chemoresistance in CRC cells while downregulation of them reverses the malignant phenotypes of cancer cells. In brief, CCAT 1 serves as a potential screening, diagnostic and prognostic biomarker in CRC, it also serves as a potential therapeutic marker to treat CRC patients.

Abstract Image

查看原文本刊更多论文

ccat1 -结直肠癌中关键的致癌长链非编码RNA。

结直肠癌(CRC)在全球男性和女性中都被列为第三大最常见的癌症和第二大致命的癌症。目前，结直肠癌患者的治愈率和5年生存率仍然较低。因此，发现一种新的分子生物标志物，可用于改善CRC的筛查、诊断、预后和治疗，将是有益的。长链非编码RNA结肠癌相关转录物1 (CCAT 1)在结直肠癌中被发现过表达，并与结直肠癌的发生和治疗结果相关。CCAT 1具有高度的特异性和敏感性，易于在结直肠癌组织中检测到，在结直肠癌癌前和恶性组织中均显著过表达。此外，CCAT 1与结直肠癌的临床表现和晚期特征相关，如淋巴结转移、高瘤结转移分期、分化、侵袭、远处转移等。此外，它们可以通过不同的作用机制上调致癌的c-MYC并负向调节microrna。此外，失调的CCAT 1也增强了CRC细胞的化疗耐药，而下调CCAT 1可逆转癌细胞的恶性表型。总之，CCAT 1在结直肠癌中作为一种潜在的筛查、诊断和预后的生物标志物，也可以作为治疗结直肠癌患者的潜在治疗标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Biomedical Science 医学-医学实验技术

CiteScore

4.40

自引率

15.80%

发文量

审稿时长

>12 weeks

期刊介绍： The British Journal of Biomedical Science is committed to publishing high quality original research that represents a clear advance in the practice of biomedical science, and reviews that summarise recent advances in the field of biomedical science. The overall aim of the Journal is to provide a platform for the dissemination of new and innovative information on the diagnosis and management of disease that is valuable to the practicing laboratory scientist.